Dataset

   File(s) held in another repository
Title of Dataset
Data from: Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer
Author of Dataset
Peyser, Noah D.1
Du, Yu2
Li, Hua3
Xiao, Xiao3
Chan, Timothy A.5
Grandis, Jennifer R.6
Contact
Grandis, Jennifer R.6
Date of Dataset Creation
2015-08-12
Description
Background Protein tyrosine phosphatase receptor type D (PTPRD) is a putative tumor suppressor in several cancers including head and neck squamous cell carcinoma (HNSCC). STAT3 is a frequently hyperactivated oncogene in HNSCC. As STAT3 is a direct substrate of PTPRD, we sought to determine the genetic or epigenetic alterations of PTPRD that contribute to overactive STAT3 in HNSCC. Methods We analyzed data from The Cancer Genome Atlas (TCGA) and our previous whole-exome sequencing study and summarized the mutation, methylation, and copy number status of PTPRD in HNSCC and other cancers. In vitro studies involved standard transfection and MTT protocols, as well as methylation-specific PCR. Results Our findings indicate that PTPRD mutation, rather than methylation or copy number alteration, is the primary mechanism by which PTPRD function is lost in HNSCC. We demonstrate that overexpression of wild-type PTPRD in HNSCC cells significantly inhibits growth and STAT3 activation while PTPRD mutants do not, suggesting that mutation may lead to loss of function and subsequent hyper-phosphorylation of PTPRD substrates, especially STAT3. Importantly, we determined that HNSCC cells harboring an endogenous PTPRD mutation are more sensitive to STAT3 blockade than PTPRD wild-type cells. We additionally found that PTPRD mRNA expression does not correlate with pSTAT3 expression, suggesting that alterations that manifest through altered mRNA expression, including hypermethylation and gene copy number alterations, do not significantly contribute to STAT3 overactivation in HNSCC. Conclusion PTPRD mutation, but not methylation or copy number loss, may serve as a predictive biomarker of sensitivity to STAT3 inhibitors in HNSCC.
Citation
Peyser, ND, Du, Y, Li, H, Lui, V, Xiao, X, Chan, TA, Grandis, JR. (2015). Data from: Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer. [Data File]. Genomic and proteomic data are available from The Cancer Genome Atlas (https://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm) and The Cancer Proteome Atlas (http://app1.bioinformatics.mdanderson.org/tcpa/_design/basic/index.html).
Click on “Linked Publications” to access the publication and access supporting information on figshare at https://figshare.com/articles/Loss_of_Function_PTPRD_Mutations_Lead_to_Increased_STAT3_Activation_and_Sensitivity_to_STAT3_Inhibition_in_Head_and_Neck_Cancer/1509783
Subject (RGC Codes)
M2 — Medicine, Dentistry & Health — 醫學, 牙科學及保健
  • 1204 — Cancer — 癌症
Subject (ANZSRC)
11 — MEDICAL AND HEALTH SCIENCES — 醫學與衛生科學
  • 1112 — ONCOLOGY AND CARCINOGENESIS — 腫瘤學與癌化
    • 111204 — Cancer Therapy (excl. Chemotherapy and Radiation Therapy) — 癌症治療
Keyword
PTPRD mRNA expression
STAT 3 blockade
STAT 3
STAT 3 inhibitors
pSTAT 3 expression
PTPRD mutation
STAT 3. Importantly
STAT 3 activation
HNSCC cells
STAT 3 overactivation
Neck Cancer BackgroundProtein tyrosine phosphatase receptor type D
TCGA
STAT 3 Inhibition
Gene Copy Number Alterations
Cancer Genome Atlas
mtt
copy number alteration
copy number loss
copy number status
Affiliations
  1. Univ Pittsburgh, Dept Otolaryngol, Sch Med, Pittsburgh, PA USA ; Univ Pittsburgh, Dept Pharmacol & Chem Biol, Sch Med, Pittsburgh, PA 15213 USA
  2. Univ Pittsburgh, Dept Otolaryngol, Sch Med, Pittsburgh, PA USA ; Univ Pittsburgh, Dept Pharmacol & Chem Biol, Sch Med, Pittsburgh, PA 15213 USA ; Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China
  3. Univ Pittsburgh, Dept Otolaryngol, Sch Med, Pittsburgh, PA USA
  4. Univ Hong Kong, Pharmacogen & Precis Therapeut Lab, Dept Pharmacol & Pharm, Hong Kong, Hong Kong, Peoples R China ; Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China
  5. Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA ; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA
  6. Univ Calif San Francisco, Dept Otolaryngol, San Francisco, CA 94143 USA